# WuXi Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wuxi-diagnostics

- Industry: Healthcare IT
- Headquarters: Shanghai, China
- Website: www.wuxidiagnostics.com
- Total disclosed funding: $150M
- Latest round: Series B (Feb 23, 2021)
- Investors on record: 6

## About

Established 2018 and based in Shanghai, China, WuXi Diagnostics is an integrated healthcare company that provides platform-based innovative diagnostic services. Headquartered in Shanghai, the company has a CAP-accredited medical laboratory with full-disciplinary practice qualifications, an ISO13485 production quality management system-certified global industrialization base in Suzhou, and an innovation project center in Rochester, U.S.A. In 2020, the company will start a global strategic cooperation with Thermo Fisher and Mayo Clinic on Corona Virus Testing. In February 2021, the company closed a round of USD 150 million series B funding.

The company has created the Disease Diagnostic Enabling Package, a one-stop diagnostic decision-making solution for hospitals and doctors, integrating clinical diagnostic technology, diagnostic paths and algorithms, and clinical medicine content system, covering four major clinical application scenarios, namely, early screening and early diagnosis, accurate diagnosis, assisted decision-making, and prognostic management.

## Funding rounds

- Series B, Feb 23, 2021, $150M — CCB International Asset Management, Thermo Fisher Scientific Inc., YF Capital, Sunland Capital, Shiyu Capital, ABC International Capital

## Investors

- CCB International Asset Management (https://capitalatlas.ai/funds/ccb-international-asset-management) — Series B
- Thermo Fisher Scientific Inc. — Series B
- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series B
- Sunland Capital — Series B
- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Series B
- ABC International Capital (https://capitalatlas.ai/funds/abc-international-capital) — Series B